Abstract
Lynch syndrome (LS) is a hereditary cancer predisposition caused by germline mutations in mismatch repair (MMR) genes. While the "classical" phenotype involves both MMR protein loss (dMMR) and high microsatellite instability (MSI-H), this study demonstrates that extraintestinal and metastatic tumors frequently exhibit "non-classical" phenotypes. In these cases, tumors remain microsatellite stable (MSS) or low (MSI-L) despite the absence of repair proteins, posing a diagnostic challenge for standard screening protocols.
Introduction
Lynch syndrome is traditionally identified through a two-step molecular screening process: immunohistochemistry (IHC) to detect dMMR and PCR-based testing for MSI. In colorectal cancers, these two markers are highly concordant. However, the reliability of MSI as a surrogate for dMMR in extraintestinal tumors—such as those of the bladder, adrenal gland, or pelvic cavity—is less clear. This study investigates the heterogeneity of MSI status across different anatomical sites within the same LS patients.
Methodology
The researchers analyzed four patients diagnosed with LS between 2018 and 2022. The study employed a multi-modal diagnostic approach:
- Immunohistochemistry (IHC): To confirm the loss of MLH1, PMS2, MSH2, or MSH6 proteins.
- MSI Testing: Utilizing the NCI 2B3D panel and a 6-marker single nucleotide site panel.
- Next-Generation Sequencing (NGS): To identify germline and somatic mutations.
- Methylation Analysis: To exclude sporadic MLH1 silencing.
Crucially, the study performed multi-site sampling, comparing primary colorectal tumors with extraintestinal primaries and metastatic lesions in the same individuals.
Key Results: The MSI-dMMR Gap
The most significant finding was the discrepancy between protein expression and genetic instability across different organs. While IHC showed a consistent loss of the relevant MMR protein across all tumor sites, MSI status varied dramatically.
Case Observations:
- Case 1 & 2 (MSH6 mutations): Colorectal tumors were MSI-H, but a bladder tumor was MSI-L and pelvic metastases were MSS. The authors attribute this to the "leaky" nature of MSH6, where other proteins like MSH3 may partially compensate for its loss in certain tissues.
- Case 3 (MSH2 mutation): While the rectal primary was MSI-H, an adrenal gland tumor was MSS and a chest wall metastasis was MSI-L.
- Consistency of IHC: Unlike MSI, IHC results were perfectly consistent across all sites, correctly identifying the protein deficiency regardless of the tumor's location or MSI status.
Clinical Implications
These findings suggest that MSI testing alone is insufficient for screening extraintestinal tumors in suspected Lynch syndrome cases. Relying on MSI status could lead to false-negative results in non-colorectal tissues, potentially delaying diagnosis or disqualifying patients from beneficial immunotherapies.
Conclusion
The "non-classical" phenotype—dMMR combined with MSS or MSI-L—is a significant feature of extraintestinal and metastatic tumors in Lynch syndrome. Clinicians should prioritize IHC over MSI testing when evaluating non-colorectal tumors to ensure accurate diagnosis and treatment planning. Future research is needed to determine the biological mechanisms that allow certain tissues to maintain microsatellite stability despite a lack of functional mismatch repair proteins.
Summary updated